Eikon Therapeutics, a Phase 2 biotech developing in-licensed therapies for immuno-responsive cancers, raised $381 million in an upsized IPO by offering 21.2 million shares at $18, the high end of the range of $16 to $18. The company originally planned to offer...read more
Updated Monday, 2/2. Eight IPOs raising at least $100 million are currently scheduled for the week ahead. If all eight deals price, it would be the busiest week for sizable offerings since 2021. Only one other week over the past four years has produced seven...read more
Eikon Therapeutics, a Phase 2 biotech developing therapies for immuno-responsive cancers, announced terms for its IPO on Wednesday. The Millbrae, CA-based company plans to raise $300 million by offering 17.6 million shares at a price range of $16 to $18. At...read more
Three IPOs and five SPACs priced this week. Six IPOs and two SPACs submitted initial filings. In the first sizable deal of 2026, solid tumor biotech Aktis Oncology (AKTS) priced its upsized IPO at the high end of the range to raise $318 million at a $1.0...read more
Immuno-responsive cancer biotech Eikon Therapeutics prices upsized IPO at $18 high end
Eikon Therapeutics, a Phase 2 biotech developing in-licensed therapies for immuno-responsive cancers, raised $381 million in an upsized IPO by offering 21.2 million shares at $18, the high end of the range of $16 to $18. The company originally planned to offer...read more
US IPO Week Ahead: At least 8 sizable IPOs teed up in one of the busiest weeks in four years
Updated Monday, 2/2. Eight IPOs raising at least $100 million are currently scheduled for the week ahead. If all eight deals price, it would be the busiest week for sizable offerings since 2021. Only one other week over the past four years has produced seven...read more
Immuno-responsive cancer biotech Eikon Therapeutics sets terms for $300 million IPO
Eikon Therapeutics, a Phase 2 biotech developing therapies for immuno-responsive cancers, announced terms for its IPO on Wednesday. The Millbrae, CA-based company plans to raise $300 million by offering 17.6 million shares at a price range of $16 to $18. At...read more
US IPO Weekly Recap: Aktis Oncology leads as first sizable 2026 IPO
Three IPOs and five SPACs priced this week. Six IPOs and two SPACs submitted initial filings. In the first sizable deal of 2026, solid tumor biotech Aktis Oncology (AKTS) priced its upsized IPO at the high end of the range to raise $318 million at a $1.0...read more